Improving access to intestinal stem cells as a step toward intestinal gene transfer

Area of Science:

• Gastroenterology
• Gene Therapy
• Biomedical Engineering

Background:

• Intestinal mucus is a major barrier to lumenal somatic gene therapy.
• Epithelial stem cells, the target for gene transfer, are located deep within intestinal crypts.
• Current methods lack effective in vivo mucus removal without damaging the epithelium.

Purpose of the Study:

• Develop procedures to improve access to intestinal stem cells.
• Achieve in vivo mucus removal without damaging the underlying epithelium.
• Enhance mucus removal from the crypt lumen for gene therapy applications.

Main Methods:

• Evaluated lumenal distension for improved crypt access.
• Tested mucolytic agents dithiothreitol (DTT) and N-acetyl-cysteine (NAC) for mucus removal.
• Investigated the use of pilocarpine to enhance mucus release from crypts.

Main Results:

• Lumenal distension shortened villi and widened intervillus spacing, improving crypt access.
• NAC and DTT removed mucus between villi but not from the crypt lumen.
• Intraperitoneal pilocarpine administration 30 minutes prior to mucolytic washes significantly eradicated mucus down into the crypt lumen.
• This mucus removal effect persisted for 3-4 hours in undisturbed intestinal segments.

Conclusions:

• Pilocarpine administration enhances the efficacy of mucolytic agents for deep crypt mucus removal.
• Combined approach of lumenal distension and pilocarpine-mediated mucus clearance improves intestinal stem cell accessibility.
• This strategy shows promise for advancing somatic gene therapy targeting the intestinal epithelium.